AzTrials
AzTrials

Pancreatic NecrosisNCT03788928

Predicting Pancreatic Necrosis Using mitDNA

An observational study of Pancreatic Necrosis, run by Assiut University.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Multiple predictors have been used for early pancreatic necrosis, prediction, detection, and monitoring. These include clinical score systems and circulating biomarkers. Ranson and APACHE II score systems are widely used albeit complex and time-consuming. Recently, the role of circulating biomarkers . Read more about this study

Who is it for?
Ages 16 to 70 years, men only
Conditions the study is for
Pancreatic Necrosis
What is being tested?
serum mitochondrial DNA
How many people
25 participants
Where
No sites listed yet
Study dates
Jan 2019to Dec 2020
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 16 to 70 years
  • Men only
  • No healthy volunteers
  • Child, Adult, Older adult

Study population: Patients will be enrolled from Raghi hospital ,Assiut university who will be diagnosed with acute pancreatitis

Who may be able to join

  • all patients diagnosed as acute pancreatitis using elevated serum amylase and contrast enhanced CT scan.

Who cannot join

  • Alchoholics
  • Renal impairment

Trial locations and contacts

No sites are listed yet.

Mostafa Abdul-Allah Haredi, Professor contact

+201001079913

mharidi2006@yahoo.com

Dr. Muhammad Abbas Said El-Masry, assistant prof. contact

+201272196319

masaeed2@yahoo.com

About this study

Official title: Study of Plasma mitDNA in Predicting Pancreatic Necrosis in Acute Pancreatitis

Multiple predictors have been used for early pancreatic necrosis, prediction, detection, and monitoring. These include clinical score systems and circulating biomarkers. Ranson and APACHE II score systems are widely used albeit complex and time-consuming. Recently, the role of circulating biomarkers . Of these novel biomarkers, only CRP has been used routinely in cases of pancreatic necrosis prediction. Mitochondrial DNA (mtDNA) is an extra chromosomal genome occurring in the mitochondria of eukaryotic cells. High levels of mtDNA suggest the presence of pancreatic necrosis and close observation should be given to avoid the development of SAP and pancreatitis infection.

Read the detailed description

Acute pancreatitis (AP) is inflammation of the pancreas that can become a fatal disease or lead to severe complications . It is characterized clinically by abdominal pain and by increased pancreatic enzyme levels in the blood or urine. Gallstone migration and alcohol abuse are the two major risk factors for AP in humans . According to the updated Atlanta classification, AP is generally divided into mild, moderate or severe pancreatitis according to the presence or absence of multiple organ failure (MOF) or local or systemic complications . Mild pancreatitis has a good prognosis with rapid recovery. The late consequences of AP include impaired pancreatic exocrine function and glucose tolerance, diabetes and development of chronic pancreatitis . Moderately severe AP is characterized by the presence of transient organ failure, local complications or exacerbation of comorbid disease . About one-third of patients with AP develop severe necrotizing pancreatitis with persistent MOF and a high mortality rate. The main goals in the clinical management of AP are adequate fluid resuscitation and the prevention of MOF . Both genetic and environmental factors affect the development and severity of pancreatitis .

Although the pathogenic mechanisms remain largely unknown, increasing evidence suggests that damage-associated molecular pattern molecules (DAMPs) play a central role in the pathogenesis of AP. DAMPs link local tissue damage to systemic inflammation response syndrome (SIRS), which, if severe or sustained, can lead to subsequent MOF and even death . Most DAMPs are recognized by membrane-bound and cytosolic pattern recognition receptors (PRRs) expressed by both immune and nonimmune cell types. This triggers downstream signaling and manifests as sterile inflammation .

The development of AP involves a complex cascade of events , which start with injury or disruption of the pancreatic acini, which then permits the leakage of active pancreatic enzymes including amylolytic, lipolytic and proteolytic enzymes that destroy local tissues. This results in edema, vascular damage, hemorrhage and cell death . In addition to oxidative stress and calcium overload , hypotension and low acinar pH contribute to these initiation processes. After initial production of active pancreatic enzymes, local cell death and systemic inflammation ensue.

Mitochondria, the energy factories of cells, regulate pancreatic cell death through control of the production of adenosine triphosphate (ATP) and reactive oxygen species (ROS), as well as calcium . Dysfunction of mitochondrial calcium uptake and efflux, including elevation of cytosolic calcium from the endoplasmic reticulum, can cause mitochondrial calcium overload, which leads to enhanced generation of mitochondrial ROS and mitochondrial membrane permeabilization. Mitochondria dysfunction-mediated oxidative injury results in endoplasmic reticulum stress, lysosomal damage and the release of proteases (for example, cathepsin and trypsin) to degrade cytosolic proteins that cause pancreatic acinar cell death . Dead, dying and injured pancreatic acinar cells release intra-cellular contents, including DAMPs (for example, high mobility group box 1 [HMGB1], DNA, histones and ATP), which in turn promote infiltration of various immune cells (for example, neutrophils, monocytes and macrophages) and activation of inflammatory signaling pathways.

The severity of experimental AP correlates with the extent and type of cell injury and death. Although multiple forms of cell death exist in physiological and pathological conditions , necrosis and apoptosis are the most widely studied types in both clinical and experimental AP . Necrotic cells are capable of activating proinflammatory and immunostimulatory responses by releasing DAMPs and other molecules, whereas apoptosis is usually considered immunologically silent because the cytoplasmic content is packaged in apoptotic bodies and these membrane-bound cell fragments are rapidly taken up and degraded by phagocytes or autophagy .

Why is the immune system so concerned with cell death? The current notion is that DAMPs released or exposed from dying or dead cells contribute to inflammatory and immune responses to remove dead cells and initiate tissue healing . Failure of this control mechanism can lead to uncontrolled inflammation and serious diseases such as sepsis, arthritis, atherosclerosis, lupus and cancer.

Mitochondria are now recognized not only as central players in cell death but also as an important source of DAMPs. mit-DAMPs, including mitDNA, N-formyl peptides, transcription factor A (TFAM, a mitochondrial HMGB1 homologue) and ROS, play emerging roles in inflammation by the activation of neutrophils, monocytes and macrophages .

The clinical course of AP is generally mild; however, nearly 25% of patients progress into severeAP (SAP) which consists of organ failure and/or pancreatic necrosis (PNec) . Although advances in the diagnosis and management have been made, AP remains a major healthissue to the society, PNec is a major complication of AP which manifests as non-opacified parenchyma with intravenous contrast, as identified via contrast-enhanced CT (CECT) scan. Patients with PNec are more likely to develop pancreatic infection and suffer a greater risk for mortality . Currently,CECT scans remain the "gold standard" to diagnosis PNec clinically . However, the extent of PNec is best seen about 3 days after the presentation of disease and may be missed in early CT scan. In addition, repeated CT scanningis not convenient to monitor changes in necrosis, most not ably for those who are receiving mechanical ventilation or hemofiltration.

Multiple predictors have alternatively been used for early PNec prediction, detection, and monitoring. These include clinical score systems and circulating biomarkers. Ranson and APACHE II score systems are widely used albeit complex and time-consuming. Recently, the role of circulating biomarkers, such as peak creatinine levels, C-reactive protein(CRP), and leptin, has been investigated . Of these novel biomarkers, only CRP has been used routinely in casesof PNec prediction. It is reported that CRP levels higher than 150 mg/l were 86% sensitive, but only 46% specific for pancreatic necrosis . Thus, additional investigationof these novel biomarkers is necessary to further improve PNec prediction.

Mitochondrial DNA (mtDNA) is an extrachromosomal genome occurring in the mitochondria of eukaryotic cells.

Normally, it is strictly contained in mitochondria and notexposed to the innate immune system even following cellapoptosis. However, in times of cell death elicited bystress (e.g., trauma and sepsis), mtDNA is released into systemic circulation and leads to an array of inflammatory reactions . Elevated mtDNA levels have been reported in a variety of clinical situations, including trauma,severe sepsis , and cancer . As PNec is caused by intracellular activation of digestive enzymes and autodigestion.

New therapeutic methods targeting PNec such as endoscopic ultrasound guided transmural drainage and necrosectomy are being tested. Early identification of PNec will be helpful for early treatment. High levels of mtDNA suggest the presence of PNec and close observation should be given to avoid the developmentof SAP and pancreatitis infection.

Necrotic substances released into the blood stimulate the production of inflammatory cytokines and mediators, trigger an inflammatory cascade and eventually lead to the SIRS or multiple organ dysfunction syndrome.

Being tested
serum mitochondrial DNA
Medical subject headings
Pancreatitis, Acute Necrotizing

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • serum mitochondrial DNADiagnostic test

    serum mitochondrial DNA will be measured using RT-PCR within first 72 hours of symptoms of acute pancreatitis

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. level of serum mitochondrial DNA

    level of serum mitochondrial DNA in severe acute pancreatitis

    Measured: baseline

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted28 Dec 2018
  2. Study startJan 2019 (estimated)
  3. Primary completionJan 2020 (estimated)
  4. Study completionDec 2020 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Case only
Time perspective
Cross-sectional
Enrolment
25 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03788928
Sponsor's protocol ID
mitDNA in acute pancreatitis
Status last verified
Dec 2018
First submitted
25 Dec 2018
Last updated
28 Dec 2018
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided

Publications

  • Wu L, Xu W, Wang F, Lv T, Yin Z, Song Y. Plasma mtDNA Analysis Aids in Predicting Pancreatic Necrosis in Acute Pancreatitis Patients: A Pilot Study. Dig Dis Sci. 2018 Nov;63(11):2975-2982. doi: 10.1007/s10620-018-5227-9. Epub 2018 Aug 9.

    PubMed 30094625

Questions about this trial

What is this clinical trial studying?

An observational study of Pancreatic Necrosis, run by Assiut University.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 28 Dec 2018. Status can change between updates, so confirm with the study contact before making plans.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Mostafa Abdul-Allah Haredi, Professor (+201001079913, mharidi2006@yahoo.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

level of serum mitochondrial DNA (time frame: baseline). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT03788928, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Dec 2018.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in